Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension

Abstract

ID is more prevalent in SSc-PH than in SSc-nonPH patients and is associated with exercise impairment in both SSc-PH and SSc-nonPH. In addition, ID SSc-PH patients have a significantly worse survival compared with non-ID patients.

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

“…Iron deficiency is common in patients with PAH and has been reported in 43% of patients with IPAH, 46% of patients with SSc-PAH and 56% of patients with Eisenmenger syndrome [181][182][183]. In all of these entities, preliminary data indicate that iron deficiency may be associated with reduced exercise capacity, and perhaps also with a higher mortality, independent of the presence or severity of anaemia [181,182,184,185].…”

“…In all of these entities, preliminary data indicate that iron deficiency may be associated with reduced exercise capacity, and perhaps also with a higher mortality, independent of the presence or severity of anaemia [181,182,184,185]. Based on these data, regular monitoring of the iron status should be considered in patients with PAH and detection of an iron deficiency should trigger a search for potential reasons.…”

The Crossroads of Iron with Hypoxia and Cellular Metabolism. Implications in the Pathobiology of Pulmonary Hypertension

“…Another recent study reported that 41% of patients with systemic sclerosis-related PH are iron deficient and that patients with systemic sclerosis without PH demonstrated only a 16% prevalence of iron deficiency (11). In these observational studies, patients did not demonstrate overt anemia compared with control patients.…”

“…It has been found that iron deficiency is associated with increased morbidity and mortality in IPAH and scleroderma-related PAH (9)(10)(11)(12). Furthermore, it has been suggested that iron infusions may attenuate hypoxic vasoconstriction (13,14), and trials are underway to evaluate the effect of intravenous iron infusions in patients with primary PAH (15).…”

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

“…Niedobór żelaza jest częsty u pacjentów z PAH i został udokumentowany u 43% chorych z IPAH, 46% pacjentów z SSc-PAH i 56% pacjentów z zespołem Eisenmengera [181][182][183]. W każdej z tych jednostek wstępne dane wskazują, że niedobór żelaza może być związany ze zmniejszeniem wydolności wysiłkowej, a być może również z wyższą śmiertelnością, niezależnie od obecności lub stopnia nasilenia anemii [181,182,184,185].…”